Unbalanced Immune System: Immunodeficiencies and Autoimmunity

Giuliana Giardino, Vera Gallo, Rosaria Prencipe, Giovanni Gaudino, Roberta Romano, Marco De Cataldis, Paola Lorello, Loredana Palamano, Chiara Di Giacomo, Donatella Capalbo, Emilia Cirillo, Roberta D’Assante and Claudio Pignata*

Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy

Increased risk of developing autoimmune manifestations has been identified in different primary immunodeficiencies (PIDs). In such conditions, autoimmunity and immune deficiency represent intertwined phenomena that reflect inadequate immune function. Autoimmunity in PIDs may be caused by different mechanisms, including defects of tolerance to self-antigens and persistent stimulation as a result of the inability to eradicate antigens. This general immune dysregulation leads to compensatory and exaggerated chronic inflammatory responses that lead to tissue damage and autoimmunity. Each PID may be characterized by distinct, peculiar autoimmune manifestations. Moreover, different pathogenetic mechanisms may underlie autoimmunity in PID. In this review, the main autoimmune manifestations observed in different PID, including humoral immunodeficiencies, combined immunodeficiencies, and syndromes with immunodeficiencies, are summarized. When possible, the pathogenetic mechanism underlying autoimmunity in a specific PID has been explained.

Keywords: autoimmunity, immunodeficiency, autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus

INTRODUCTION

Immunodeficiencies and autoimmunity may be considered two opposite conditions, deriving from different alterations of the immune system. However, the evidence that primary immunodeficiencies (PIDs) are often associated with different autoimmune manifestations suggests that they could share common pathogenetic mechanisms, which result in a broad immune dysregulation.

Immune system becomes self-tolerant through two main mechanisms called central and peripheral tolerance. As for T cells, central tolerance takes place within the thymus and is mediated by medullary thymic epithelial cells (mTEC), which express tissue-specific antigens under the control of the transcription factor autoimmune regulator (AIRE) (1–3). Developing T-cells recognizing self-antigens receive a signal to die via programmed cell death and, thereby, are deleted, through negative selection, from the T-cell repertoire (4, 5). As for B cells, negative selection of autoreactive cells takes place within the bone-marrow. Different mechanisms, including immunological ignorance, anergy, and suppression through regulatory T cells (Treg) are implicated in the control of self-reactive cells, which escape central tolerance and reach the periphery. For example, the ligation of T-cell receptor (TCR), in the absence of costimulatory molecules, makes the cells unable to express effector functions like cytokine secretion, leading to anergy (6). The control of the expression of the costimulatory molecules CD80 and CD86 is a major mechanism of peripheral tolerance (6).

In some cases, the inability to eradicate foreign antigens may lead to an exaggerated chronic inflammatory responses and autoimmunity (7–10), through several mechanisms, including
molecular mimicry, by-stander activation, epitope spreading, and cryptic antigens.

Each PID is characterized by distinct, peculiar autoimmune manifestations (Tables 1 and 2), but the mechanisms may differ.

In this review, we will describe the main autoimmune manifestations observed in different PIDs, including humoral immunodeficiencies, combined immunodeficiencies, and syndromes with immunodeficiencies, and, when possible, we will try to explain the pathogenetic mechanism underlying autoimmunity in a specific PID.

**AUTOIMMUNITY IN HUMORAL IMMUNODEFICIENCIES**

**Selective IgA Deficiency**

Selective IgA deficiency (SIgAD) is the most common PID in humans (11). According to European Society for Immunodeficiencies (ESID) criteria, SIgAD is defined by the presence of serum IgA levels <0.07 g/l in the absence of IgG and IgM deficiencies, after the age of 4 years (12). Patients with SIgAD have an increased risk to develop allergies and autoimmune manifestations, including juvenile idiopathic arthritis, rheumatoid arthritis, thrombocytopenic purpura, hemolytic anemia, inflammatory bowel disease (IBD), Sjögren's disease, polyarteritis nodosa, systemic lupus erythematosus (SLE), celiac disease, and insulin-dependent diabetes mellitus (T1D) (Table 1) (13). Little is known about the pathogenesis of SIgAD and the predisposition to autoimmunity in these patients. Specific human leukocyte antigen (HLA) haplotypes, including 8.1, DR7, DQ2, DR1, and DQ5 have been identified in patients with SIgAD at higher risk autoimmune diseases (14), such as SLE, autoimmune thyroiditis, and celiac disease. In a recent study, the identification of single nucleotide polymorphisms in the IF1H1 gene encoding for an interferon inducible RNA helicase 1 protein and of a mutation in the CLEC16A gene in SIgAD patients has been associated with the development of autoimmune manifestations (14). Jacob et al. hypothesized that IgA exerts a protective role against autoimmunity. In particular, the interaction between the Fc fragment of IgA receptor and the immunoreceptor tyrosine-based activation motif deactivates the

| TABLE 1 | Autoimmune manifestations in humoral immunodeficiencies. |
|-----------------|----------------------------------------------------------|
| 1. SIgAD | Juvenile idiopathic arthritis  
Rheumatoid arthritis  
ITP, AHA  
IBD  
Sjögren’s disease  
Polyarteritis nodosa  
SLE  
Celiac disease  
T1D |
| 2. CVID | ITP, AHA  
SLE  
IBD |
| 3. PRKCD deficiency | Glomerulonephritis  
Polychondritis  
Antiphospholipid syndrome  
Celiac disease  
T1D |
| 4. LRBA deficiency | IBD  
AHA, ITP  
Granulomatous-lymphocytic interstitial lung disease  
T1D  
Neutropenia  
Chronic autoimmune hepatitis  
Eczema  
Uveitis  
Alopecia |
| 5. Hyper-IgM syndrome | IBD  
Seronegative arthritis  
Hypothyroidism  
SLE  
Autoimmune hepatitis  
ITP, AHA  
T1D  
Uveitis |

SIgAD, selective IgA deficiency; ITP, immune thrombocytopenia; AHA, autoimmune hemolytic anemia; IBD, inflammatory bowel disease; SLE, systemic lupus erythematosus; T1D, type 1 diabetes mellitus; CVID, common variable immunodeficiency.

**TABLE 2 | Autoimmune manifestations in combined immunodeficiencies and in syndromes with immunodeficiency.**

| 1. RAG-1/2 deficiency | RMRP, ADA, IL2RG, Artemis, DNA ligase IV, ZAP70, and IL7Ra deficiency  
Omenn syndrome (erythroderma, alopecia, hepatosplenomegaly, and lymphadenopathy) |
| 2. PNP-deficiency, and mutations of ADA, DNA ligase IV, Cernunnos, ORAI1 and STIM1, and hypomorphic RAG1 mutations | ITP, AHA |
| 3. Wiskott–Aldrich | AHA  
Autoimmune neutropenia  
Vasculitis  
IgA nephropathy  
Polyarthritis  
IBD |
| 4. DiGeorge syndrome | ITP, AHA  
Autoimmune arthritis  
Autoimmune hepatitis  
Vitiligo  
IDB  
Autoimmune endocrinopathy |
| 5. Ataxia telangiectasia | Psoriasis  
Autoimmune thyroid disease |
| 6. STAT1 gain of function | Autoimmune thyroid disease  
IPEX-like phenotype (eczema, enteropathy, T1D, hypothyroidism, and growth hormone insufficiency) |
| 7. STAT3 gain of function | Early onset autoimmunity (neonatal diabetes, enteropathy, desquamative interstitial pneumonitis, and posterior uveitis) |

IPT, immune thrombocytopenia; AHA, autoimmune hemolytic anemia; IBD, inflammatory bowel disease.
pathways of immune response carrying this motif through a partial phosphorylation (15). Moreover, the evidence of antibodies to bovine milk proteins in over 60% of IgA deficient patients may help explaining the association between SlgAD and inflammatory diseases of gastrointestinal tract (16, 17).

**Common Variable Immunodeficiency**

Common Variable immunodeficiency (CVID) is a heterogeneous group of disorders characterized by a primary antibody deficiency, usually manifesting between the second and fourth decades of life with a mean age at onset of 26.3 years (18). It is the second most common immunodeficiency with an estimated prevalence ranging from 0.073 to 0.977 living patients per 100,000 inhabitants (19). According to the ESID diagnostic criteria, CVID should be taken into account in presence of a marked decrease of IgG and IgA with or without low IgM levels (measured at least twice; <2SD of the normal levels for their age) (http://esid.org/ Working-Parties/Registry/Diagnosis-criteria). Moreover, all of the following criteria should be fulfilled: poor antibody response to vaccines (and/or absent isohemagglutinins) or low switched memory B cells (<70% of age-related normal value); secondary causes of hypogammaglobulinemia have been excluded diagnosis is established after the 4th year of life; no evidence of profound T-cell deficiency (http://esid.org/Working-Parties/Registry/Diagnosis-criteria). More than 25% of CVID patients develop autoimmune complications (18, 20). Other medical conditions may include gastrointestinal infectious or inflammatory disease, lymphadenopathy, splenomegaly, and hematological malignancies (21). Cryoglobulinemia is the most common manifestation. Immune thrombocytopenia (ITP) has been found in up to 14% of patients and autoimmune hemolytic anemia (AHA) in up to 7% (22). In most cases (about 60%), the cryoglobulinemia precedes the identification of hypogammaglobulinemia (23). SLE has been reported in some rare CVID patient (24), predominantly females (89%). In about 50% of patients, CVID developed within 5 years of the diagnosis of SLE (24). Some patients experience an improvement in SLE symptoms when hypogammaglobulinemia appears (24). Hypogammaglobulinemia can develop because of the use of immunosuppressive treatment (i.e., corticosteroids or immunosuppressants). Unlike CVID, the cessation of therapy should solve hypogammaglobulinemia. Nevertheless, in some occasion, the duration of post-cessation hypogammaglobulinemia can be very prolonged, making difficult to understand its origin (25). IBD has been reported in 6–10% of CVID patients (Table 1) (22). Many different alterations could help explain the predisposition to autoimmune manifestations. In a subgroup of CVID patients, IL-7 levels were found to be increased (26, 27). IL-7 plays a key role in the expansion of autoreactive T-cell clones in the lymphopenic host (26, 27). Moreover, reduced levels of switched memory B cells and increased levels of activated CD21-low B cells have been associated with autoimmune manifestations in CVID. Increased levels of CD21-low B cells have been identified in SLE, rheumatoid arthritis, and cryoglobulinemia, suggesting a role for these cells in the pathogenesis of autoimmunity (28–30). Most CVID patients present with elevated BAFF levels (27). Of note, increased BAFF levels sustain the expansion of CD21-low B cells in CVID (31). Moreover, studies show that overexpression of BAFF in mice leads to B-cell hyperplasia, splenomegaly, and autoimmunity (32, 33). Different genetic mutations, including TACI, ICOS, BAFF-R, CD20, and CD21 have been associated with increased risk of developing CVID (34–40). Among these genetic alterations, autoimmunity is most common in TACI alterations [18/50 (36%) vs. 112/490 (23%) in wt TACI CVID], in particular, heterozygous C104R mutations (11/20 patients, 55%) (41).

**PRKCD Deficiency**

A CVID-like disorder associated with multiple features of immune dysregulation, including glomerulonephritis, lymphadenopathy, relapsing polychondritis, and antiphospholipid syndrome has been recently described in a 12-year-old patient born to consanguineous parents of Turkish origin (42). Genetic studies revealed a mutation of PRKCD gene, leading to a complete absence of the protein. PRKCD deficiency has also been reported in three siblings with LES (Table 1) (43). PRKCD plays a key role in the regulation of cell survival, proliferation, and apoptosis (44). PRKCD deficiency in mice seems to be related to a defective deletion of autoreactive B cells during B-cell development, due to impaired proapoptotic extracellular signal-regulated kinase signaling (45, 46).

**LRBA Deficiency**

LPS-responsive beige-like anchor protein (LRBA) deficiency is a novel PID caused by either homozygous or compound heterozygous mutations in LRBA that abolish LRBA protein expression. This PID is characterized by early onset hypogammaglobulinemia, autoimmunity manifestations, susceptibility to IBD, and recurrent infections (47). However, it has been also described in patients with IBD with or without antibody deficiency (48, 49), in patients with autoimmune manifestations without hypogammaglobulinemia (50), or in patients with immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome (IPEX)-like disorder (51). The main clinical manifestations of LRBA deficiency are immune dysregulation (95%), followed by organomegaly (86%) and recurrent infections (71%). The most common autoimmune manifestations are enteropathy (59%), AHA (50%), and ITP (50%). A lower number of patients presented granulomatous-lymphocytic intestinal lung disease (36%), T1D or neutropenia (22%), chronic autoimmune hepatitis (13%), eczema and uveitis (9%), and alopecia (4.5%) (Table 1). LRBA is a highly conserved multidomain protein implicated in regulating endosomal trafficking, cell proliferation, and survival. LRBA deficiency is associated with increased apoptosis and altered phenotype of Treg cells, which express lower levels of key effector proteins involved in Treg cell suppression, such as CD25 and CTLA-4. This results in decreased frequency, aberrant phenotype, and decreased suppressive function of such cells. These alterations might play a critical role in the ubiquitous autoimmune manifestations of the disease.

**CTLA-4 Haploinsufficiency**

CTLA-4 haploinsufficiency has been recently associated with lymphoproliferation, lymphocytic infiltration, autoimmunity,
peripheral B-cell lymphopenia, hypogammaglobulinemia, and increased CD21lo B cells (52). In mouse models, homozygous CTLA-4 deficiency leads to a lethal autoimmune phenotype characterized by multorgan infiltrative inflammation and destruction (53, 54) resembling FOXP3 deficiency (55–57). CTLA-4 plays a key role in immune tolerance. Recent studies show that CTLA-4 is able to suppress the expression of CD80 and CD86 from antigen presenting cells (APCs) via transendocytosis (58). The depletion of the costimulatory ligands reduces T cell activation (59).

**Activated Phosphoinositide 3-Kinase δ Syndrome**

Activated phosphoinositide 3-kinase δ (APDS) 1 and 2 are PID resulting from autosomal dominant mutations in PIK3CD and PIK3R1, respectively (60, 61). Autoimmune manifestations are reported in 34% of APDS1 patients. The clinical manifestations included cytopenias (AHA or tri-lineage cytopenia), glucocerebrosidase, exocrine pancreatic insufficiency, autoimmune thyroid disease, seronegative arthritis, recurrent pericarditis, sclerosing cholangitis, and gastrointestinal nodular mucosal lymphoid hyperplasia (61). Autoimmune manifestations have been reported in the 17% of the APDS2 patients. They included ITP, AHA, Evans syndrome, T1D, chronic arthritis, autoimmune hepatitis, and chronic eczema (60). PI3Kδ is implicated in the regulation of Treg cell function. Studies suggest that PI3K δ is an important target for the treatment of different autoimmune conditions.

**Hyper-IgM Syndrome**

Hyper-IgM syndrome (HIGM) is a group of disorders characterized by alterations of immunoglobulin receptor isotype switching, leading to normal or elevated IgM antibody and very low IgA, IgG, and IgE antibodies (62). Alterations in different genes implicated in CD40–CD40L pathway involved in B cell activation, class switch recombination or somatic hypermutation have been identified in HIGM. Seven different forms of HIGM have been till now described. Most of the cases (65–70%) are due to mutations of the gene encoding for CD40 ligand (CD40L) on the X chromosome, leading to HIGM1 (63). The other forms are due to mutations of AID (HIGM2), CD40 (HIGM3), UNG (HIGM5), NEMO (HIGM6), and IκBα (HIGM7). No genetic defect has been so far identified for HIGM4.

Autoimmunity has been described in all forms of HIGM. HIGM1 patients have an increased risk to develop IBD, seronegative arthritis, hypothyroidism, and SLE (64). In the 21% of patients affected with HIGM2 autoimmune hepatitis, ITP, T1D, IDB, and uveitis have been described (65). In addition, in patients with NEMO defects, AHA, IB, and arthritis have been described (Table 1) (66). Studies on transgenic mouse models suggest that CD40–CD40L interactions is involved in the elimination of autoreactive B cells (67). In fact, an increase of circulating polyreactive B cells and a significant decrease of CD25+Foxp3+Treg cells have been reported in CD40L-deficient patients suggesting defects of the peripheral B-cell tolerance mechanism. An imbalanced production of cytokines, including as IL-1, IL-8, IL-6, IL-10, IL-12, and tumor necrosis factor (TNF-α) may be observed in CD40-deficient patients (68). This impairment is the consequence of the involvement of CD40–CD40L interaction in T-cell-dependent macrophage-mediated immune response, implicated in the maturation of dendritic cells and regulation of the T-cell activation. The transcription factor NFκB plays a key role in the regulation of pro-inflammatory responses. Recent studies suggest that gut epithelial cells are directly implicated in the control of epithelial integrity and the regulation of the interaction between the mucosal immune system and gut microflora. In mice, NEMO deficiency causes a severe chronic intestinal inflammation, which has been associated with apoptosis of colonic epithelial cells, impaired expression of antimicrobial peptides, and translocation of bacteria into the mucosa. The chronic inflammatory response observed within the colon, is dominated by innate immune cells, as suggested by the upregulation of IL1b, IL6, TNF, and Cc12 and by the infiltration of large numbers of dendritic cells and granulocytes in the colon. Eventually, also T lymphocytes are involved, as suggested by the presence of lymphoid follicles and a massive infiltration with CD4+ T cells in the gut mucosa.

**COMBINED IMMUNODEFICIENCIES**

Severe combined immunodeficiency (SCID) is a group of different PIDs characterized by a severe deficiency of the cellular and humoral immune system. SCID phenotype may be due to a variety of different mutations. From a clinical point of view, SCID is characterized by recurrent severe infections, chronic diarrhea, and failure to thrive (69, 70). The clinical presentation may drive the diagnosis toward a specific molecular cause of SCID (69). Patients affected with SCID often develop autoimmune manifestations. This may appear surprising in that SCID patients, who are unable to mount any immune response to foreign pathogens, may paradoxically develop autoimmune phenomena. Alterations in both central and peripheral tolerance have been described in SCID patients (71).

**Autoimmunity in Omenn Syndrome**

Omenn syndrome (OS) is a SCID inherited in an autosomal recessive manner, caused by homozygous or compound heterozygous mutations in recombinase activating gene 1 (RAG1) or RAG2, implicated in V(D)J recombination, which represents a crucial step in T- and B-cell differentiation. OS has also been associated with hypomorphic mutations in other different genes, including RMRP, ADA, IL2RG, Artemis, DNA ligase IV, ZAP70, and IL-7Ra deficiency (72, 73). Signs of OS, including oligoclonal T-cell expansion, generalized rash, and lymphadenopathy have been reported in some patient affected with DiGeorge syndrome. This rare condition is known as atypical complete DiGeorge syndrome (74). Apart from recurrent infections, patients affected with OS also show features of autoimmunity, including erythroderma, alopecia, hepatosplenomegaly, and lymphadenopathy (Table 2). The hallmark of the syndrome is the expansion and activation of a peripheral oligoclonal population of autoreactive T cells, due to defective central (75, 76) and peripheral tolerance mechanisms (77). Studies suggest

---

*Giardino et al.* Immunodeficiencies and Autoimmunity

**Table 1**

| Autoimmune Manifestations |
|---------------------------|
| Autoimmune hepatitis, ITP, AHA, Evans syndrome, T1D, chronic arthritis, autoimmune hepatitis, and chronic eczema |

**Table 2**

| Autoimmune Manifestations |
|---------------------------|
| Autoimmune hepatitis, ITP, AHA, Evans syndrome, T1D, chronic arthritis, autoimmune hepatitis, and chronic eczema |

---

Frontiers in Pediatrics | www.frontiersonline.org 4 October 2016 | Volume 4 | Article 107
that in OS, defective AIRE expression may lead to inadequate expression of tissue-specific self-antigens by mTEC, impairing central tolerance. In these patients, the T-cell compartment is composed by a high proportion of autoreactive T cells, which are able to expand in peripheral tissues leading to the clinical symptoms. Similarly, alterations in central tolerance may be implicated in the pathogenesis of immune manifestations also in PIDs characterized by ineffective thymopoiesis, such as the DiGeorge syndrome or in SCID characterized by partial defects of the T-cell maturation, such as IL-7alpha, common γ chain, or ARTEMIS defects. The persistent infectious/inflammatory state and the presence of immunologic "space," which increases the ability of T cells to respond to an excess of cytokines or antigens, impairs peripheral tolerance in SCID patients. Treg population may be also affected in SCID patients.

Autoimmune Manifestations in SCID Due to IL7R Mutations
IL7Ra deficiency is responsible of the majority of T-B+NK+ cases (72) characterized by an increased susceptibility to severe and opportunistic infections. In a few cases, autoimmune manifestations have been reported (72, 73). Autoimmune manifestations presented with OS in one infant (73), and cytopenias in three other cases. Autoimmune cytopenias have been also described in some patients with PNP-deficiency, and mutations of ADA, DNA ligase IV, Cernunnos, and hypomorphic RAG1 mutations (Table 2) (69, 78–82).

Ca++ Channelopathies Due to Mutations in ORAI1 and STIM1
Null or loss-of-function mutations in ORAI1 or STIM1 are associated with a SCID-like disease characterized by recurrent and chronic infections, autoimmunity, ectodermal dysplasia, and muscular hypotonia in the presence of numerically intact T, B, and NK cells. Symptoms usually manifest in the first year of life. Lymphoproliferation, AHA, and ITP are very common in patients with STIM1 mutations (Table 2). Autoimmunity may derive from alterations of negative selection of autoreactive T cells and/or B cells during their development. In fact, Ca2+ signals are implicated in TCR and BCR signaling and thus potentially influence the selection thresholds in immature T and B cells. Moreover, a reduced frequency of Treg cells has been observed in STIM1-deficient patients (83, 84) and in one patient with ORAI1 p.R91W mutation.

SYNDROMES WITH IMMUNODEFICIENCY

Wiskott–Aldrich
Wiskott–Aldrich syndrome is a very rare immunodeficiency, characterized by thrombocytopenia, eczema, and recurrent bacterial infections appearing in the first months of life. Other features includes humoral and cellular immunodeficiency, defects of the innate immunity (85–87), increased risk to develop autoimmune manifestation and malignancies, impaired apoptosis (88, 89), and defective cell motility (90). The gene responsible for WAS (WASP) is located on the X chromosome and encode for WASP protein, which is only expressed in the cytoplasm of hematopoietic cells. WASP protein plays a major role in the transduction of the signals from the cell surface to the actin cytoskeleton, which regulates actin polymerization and the formation of actin filament (91, 92). WAS patients are at a higher risk of developing autoimmunity and most of WAS patients (about 40%) are affected by at least one autoimmune manifestation (93, 94). The most common autoimmune manifestations include AHA, autoimmune neutropenia, vasculitis, and IgA nephropathy with or without the association with Henoch–Schönlein purpura, polyarthritis and IBD (Table 2) (87, 93–95). Studies suggest that a defect in Treg cells could be implicated in the pathogenesis of autoimmune manifestations (96, 97). In fact, Treg cells, isolated from WAS patients, show a reduced ability to suppress effector T-cell proliferation and IFN-γ production (98, 99). On the contrary, Treg cell development is not impaired in these patients. In addition, Treg cells from WASp−/− mouse show a reduced granzyme B secretion, which results in the inability to suppress B-cell proliferation and apoptosis. Furthermore, studies on mouse models show that Treg cells from WASp−/− mouse are not able to prevent the development of autoimmunity in scurfy mice (Foxp3-deficient) (98–100). Also B cells may be implicated in the pathogenesis of autoimmune manifestations in WAS patients. Studies show that selective deletion of WASP in B cells leads to the production of autoantibodies and the development of autoimmunity (101, 102).

DiGeorge Syndrome
Autoimmune manifestations have been reported in about the 10% of patients with DiGeorge syndrome (103–105). Autoimmune disorders include mainly autoimmune cytopenias (ITP, AHA) (106–108), autoimmune arthritis (107), autoimmune hepatitis, vitiligo, IDB, and autoimmune endocrinopathy (Table 2) (109). Impaired T-cell development in an abnormal thymus may result in altered central tolerance and escape of self-reactive T. Thymic abnormality may also result in impaired generation of Treg (96, 110, 111).

Ataxia Telangiectasia
Patients with ataxia telangiectasia (A-T) have increased frequency of autoimmune disorders (112), including psoriasis and autoimmune thyroid disease (Table 2). Loss of suppressor T-cell function has been described as responsible for the development of autoimmune disease.

STAT1 Gain of Function
Increased incidence of autoimmunity has been reported in heterozygous STAT1 gain-of-function (GOF) mutations (113). The main clinical features of the syndrome include chronic mucocutaneous candidiasis (CMC) (114–118), disseminated coccidioidomycosis, and histoplasmosis (116, 119), recurrent sinopulmonary infections and pneumonias (with or without bronchiectasis), herpes virus infections, blood-borne infections, squamous cell cancer, and cerebral aneurysms (116, 120). The most common autoimmune manifestation is thyroiditis, but in...
some case patient may show an IPEX-like phenotype (121). Number and function of Treg cells are usually normal and the pathogenesis of IPEX-like disease remains unclear (121).

**STAT3 Gain of Function**

Recent studies show that activating STAT3 mutations may lead to autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease (122). The autoimmune manifestations are early onset and include neonatal diabetes and some rare disorders, such as desquamative interstitial pneumonitis and posterior uveitis (123). Patients with activating STAT3 mutations show a reduced number of Th17 cells, decreased IL-17 production, and deficiency of Treg, NK, and dendritic cells (123). Autoimmunity may develop as a consequence of the impaired Treg development.

**REFERENCES**

1. Capalbo D, Giardino G, Martino LD, Palamara L, Romano R, Gallo V, et al. Genetic basis of altered central tolerance and autoimmune diseases: a lesson from AIRE mutations. *Int Rev Immunol* (2012) 31:344–62. doi:10.3109/08830185.2012.697230

2. Gallo V, Giardino G, Capalbo D, Palamara L, Romano R, Santamaria F, et al. Alterations of the autoimmune regulator transcription factor and failure of central tolerance: APECED as a model. *Expert Rev Clin Immunol* (2013) 9:43–51. doi:10.1586/2171-0061.2013.582387

3. Capalbo D, De Martino L, Giardino G, Di Mase R, Di Donato I, Parenti G, et al. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: insights into genotype-phenotype correlation. *Int J Endocrinol* (2012) 2012:9. doi:10.1155/2012/353250

4. DeFranco S, Bonissone S, Cerutti F, Bona G, Bottarel F, Cadario F, et al. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases. *Diabetes* (2001) 50:483–8. doi:10.2337/ diabetes.30.3.483

5. Pignata C, Alessio M, Ramenghi U, Bonisso S, DiFranco D, Brusco A, et al. Clustering of distinct autoimmunity diseases associated with functional abnormalities of T cell survival in children. *Clin Exp Immunol* (2000) 121:53–8. doi:10.1046/j.1365-2249.2000.01275.x

6. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. *Nat Rev Immunol* (2007) 6:765–77. doi:10.1038/nri2153

7. Aloi G, Giardino G, Valentino L, Maio F, Gallo V, Esposito T, et al. Severe combined immunodeficiencies: new and old scenarios. *Int Rev Immunol* (2012) 31:43–65. doi:10.3109/08830185.2011.644607

8. Münz C, Lünemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? *Nat Rev Immunol* (2009) 9:246–58. doi:10.1038/nri2527.

9. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to autoimmunity. *J Autoimmun* (2001) 17:175–86. doi:10.1006/j autoimmune.2000.0492

10. Panoutsakopoulou V, Cantor H. On the relationship between viral infection and autoimmunity. *J Autoimmun* (2001) 17:341–5. doi:10.1006/j autoimmune.2000.0480

11. Yel L. Selective IgA deficiency. *J Clin Immunol* (2010) 1:10–6. doi:10.1007/s10817-009-9357-x

12. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and EISID (European Society for Immunodeficiencies). *Clin Immunol* (1999) 3:190–7. doi:10.1006/clin.1999.4799

13. Singh K, Chang C, Gershwin ME. IgA deficiency and autoimmunity. *Autoimmun Rev* (2014) 2:163–77. doi:10.1016/j.autrev.2013.10.005

14. Jørgensen GH, Ornolfsen AE, Johannesson A, Gudmundsson S, Jænæ M, Wang N, et al. Association of immunoglobulin A deficiency and elevated thyrotropin-receptor autoantibodies in two Nordic countries. *Hum Immunol* (2011) 2:166–72. doi:10.1016/j.humimm.2010.10.014

15. Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC. Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. *J Clin Immunol* (2008) 28:556–61. doi:10.1007/s10875-007-9163-2

16. Cunningham-Rundles C, Brandeis WE, Pudifin DJ, Day NK, Good RA. Autoimmunity in selective IgA deficiency: relationship to anti-bovine protein antibodies, circulating immune complexes and clinical disease. *Clin Exp Immunol* (1981) 45:299–304.

17. Pignata C, Budillon G, Monaco G, Nani E, Cuomo R, Parrilli G, et al. Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes. *Gut* (1999) 41:879–82. doi:10.1136/gut.31.8.879

18. Chapell H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. *Blood* (2008) 112:277–86. doi:10.1182/blood-2007-11-124545

19. Gathmann B, Binder N, Ehl S, Kindle G, ESID Registry Working Party. The European internet-based patient and research database for primary immunodeficiencies: update 2011. *Clin Exp Immunol* (2012) 167:479–91. doi:10.1111/j.1365-2249.2011.04542.x

20. Cunningham-Rundles C. Common variable immunodeficiency. *Curr Allergy Asthma Rep* (2001) 1:421–9. doi:10.1007/s11882-001-0027-1

21. Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. *Curr Allergy Asthma Rep* (2009) 9:347–52. doi:10.1007/s11882-009-0051-0

22. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. *Clin Immunol* (1999) 92:34–48. doi:10.1006/clim.1999.4725

23. Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). *J Autoimmun* (2005) 25:57–62. doi:10.1016/j.jaut.2005.04.006

24. Fernández-Castro M, Mellor-Pita S, Citores MJ, Muñoz P, Tutor-Ureta P, Silva L, et al. Common variable immunodeficiency in systemic lupus erythematosus. *Semin Arthritis Rheum* (2007) 36:238–45. doi:10.1016/j. semarthritis.2006.09.005

25. Yong PF, Aslam L, Kaimt MY, Khamashia MA. Management of hypogammaglobulinaemia occurring in patients with systemic lupus erythematosus. *Rheumatology* (Oxford) (2008) 47:1400–5. doi:10.1093/rheumatology/ken255

26. Holm AM, Aukrust P, Damas JK, Muller F, Halvorsen B, Froland SS. Abnormal interleukin-7 function in common variable immunodeficiency. *Blood* (2005) 105:2887–90. doi:10.1182/blood-2004-06-2423

27. Kreuzaler M, Rauh M, Salzer U, Birmelin J, Rüzi M, Grimbacher B, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. *J Immunol* (2012) 188:497–503. doi:10.4049/jimmunol.1102321

28. Warnatz K, Wehr C, Dräger R, Schmidt S, Eibel H, Schlesier M, et al. Expansion of CD19hlCD21lo/mg B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. *Immunobiology* (2002) 206:502–13. doi:10.1078/0171-2985-00198

**CONCLUSION**

Autoimmunity and immunodeficiencies represent two opposite conditions, which may coexist in the context of a general immune dysregulation. Even though different mechanisms have been identified to explain autoimmunity in PIDs, the pathogenesis of autoimmunity remains unexplained in most of the cases. Considering this strong association, underlying immunodifficiency should be always excluded in particular in presence of early onset or multiple autoimmune manifestations (124).

**AUTHOR CONTRIBUTIONS**

All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.
68. Lougari V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. *Immunol Rev* (2005) 203:48–66. doi:10.1111/j.0909-2884.2005.00239.x

69. Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. *J Allergy Clin Immunol* (2009) 6:1152–60. doi:10.1016/j.jaci.2009.10.022

70. Cirillo E, Giardino G, Gallo V, D’Assante R, Grasso F, Romano R, et al. Severe combined immunodeficiency – an update. *Ann N Y Acad Sci* (2015) 1356:90–106. doi:10.1111/nyas.12489

71. Kelly BT, Tam JS, Verbsky JW, Routes JM. Screening for severe combined immunodeficiency in neonates. *Clin Epidemiol* (2013) 5:363–9. doi:10.2147/CEPJ.S48990

72. Yu GP, Nadeau KC, Berk DR, de Saint Basile G, Lambert N, Knapnougel P, et al. Genotype, phenotype, and outcomes of nine patients with T-B+NK+SCID. *Pediatr Transplant* (2011) 15:733–41. doi:10.1111/j.1399-3046.2011.01563.x

73. Giliani S, Bonfim C, de Saint Basile G, Lanzi G, Brousse N, Koliski A, et al. Omenn syndrome in an infant with IL7RA gene mutation. *J Pediatr* (2006) 148:272–4. doi:10.1016/j.jpeds.2005.10.004

74. Vu QV, Wada T, Toma T, Tajima H, Maeda M, Tanaka R, et al. Clinical and immunophenotypic features of atypical complete DiGeorge syndrome. *Pediatr Int* (2013) 55:2–6. doi:10.1111/j.1442-200X.2012.07322.x

75. Rucci F, Poliani P, Caraffi S, Paganini T, Fontana E, Giliani S, et al. Abnormalities of thymic stroma may contribute to immune dysregulation in murine models of leaky severe combined immunodeficiency. *Front Immunol* (2011) 2:115. doi:10.3389/fimmu.2011.00015

76. Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, et al. Defect of regulatory T cells in patients with Omenn syndrome. *J Exp Med* (2001) 194(1):35–81.

77. Buck D, Malivert L, de Chasseval R, Barrass A, Fondanèche MC, Sanal O, et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. *Cell* (2006) 124:287–99. doi:10.1016/j.cell.2005.12.030

78. de Villartay JP, Lim A, Al-Mousa H, Dupont S, Déchanet-Merville J, Coumail-Gathois E, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. *J Clin Invest* (2005) 115:3291–9. doi:10.1172/JCI25178

79. Enders A, Fisch P, Schwarz K, Duffner U, Pannicke U, Nikolopoulos E, et al. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. *J Immunol* (2006) 176(8):5060–8. doi:10.4049/jimmunol.176.8.5060

80. Etzioni A, Pollack S. Autoimmune phenomena in DiGeorge syndrome. *Curr Opin Rheumatol* (2007) 124:41–8. doi:10.1016/j.clim.2007.02.001

81. Shimizu M, Nikolov NP, Ueno K, Ohta K, Siegel RM, Yachie A, et al. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. *Nat Immunol* (2005) 6:345–52. doi:10.1038/nri1718

82. Pasic SD, Djuricic S, Ristic G, Slavkovic B. Recombinase-activating gene immunodeficiency: different immunological phenotypes in three siblings. *Acta Paediatr* (2009) 98:1062–4. doi:10.1111/j.1651-2227.2009.01250.x

83. Picard C, McLaren CA, Papulos A, KHALI S, Luthy K, Hivroz C, et al. STIM1 mutations associated with X-linked adult-Onset juvenile rheumatoid arthritis-like polyarthritis in chromosome 22q11.2 deletion syndrome. *Arthritis Rheum* (1997) 40:430–6. doi:10.1002/art.1780400307
108. Davies JK, Telfer P, Cavenagh JD, Foot N, Neat M. Autoimmune cytopenias in the 22q11.2 deletion syndrome. *Clin Lab Haematol* (2003) 25:195–7. doi:10.1046/j.1365-2257.2003.00508.x

109. Brown JJ, Datta V, Browning MJ, Swift PG. Graves’ disease in DiGeorge syndrome: patient report with a review of endocrine autoimmunity associated with 22q11.2 deletion. *J Pediatr Endocrinol Metab* (2004) 17:1575–9. doi:10.1515/JPEM.2004.17.11.1575

110. Markert ML. Treatment of infants with complete DiGeorge anomaly. *J Allergy Clin Immunol* (2008) 121:1063. doi:10.1016/j.jaci.2007.12.1181

111. Markert ML, Marques J, Neven B, Devlin B, McCarthy E, Chinn I, et al. First use of thymus transplantation therapy for Foxn1 deficiency (nude/SCID): a report of two cases. *Blood* (2011) 117:688–96. doi:10.1182/blood-2010-06-292490

112. Hong R, Ammann AJ. Ataxia telangiectasia. *N Engl J Med* (1970) 283:660. doi:10.1056/NEJM197009172831220

113. Hori T, Ohnishi H, Teramoto T, Tsubouchi K, Naiki T, Hirose Y, et al. Autosomal-dominant chronic mucocutaneous candidiasis with STAT1-mutation can be complicated with chronic hepatitis and hypothyroidism. *J Clin Immunol* (2012) 32:1213–20. doi:10.1007/s10875-012-9744-6

114. Liu L, Okada S, Kong X-F, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. *J Exp Med* (2011) 210:1635–48. doi:10.1084/jem.20110958

115. Dotta L, Scomodon O, Padoan R, Timpano S, Plebani A, Soresina A, et al. Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease. *Clin Immunol* (2016) 164:1–9. doi:10.1016/j.clim.2015.12.010

116. Toubiana J, Okada S, Kong X-F, Kreins AY, Cypowyj S, Abhyankar A, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. *Blood* (2016) 127:3154–64. doi:10.1182/blood-2015-11-679902

117. Giardino G, Somma D, Cirillo E, Ruggiero G, Terrazzano G, Rubino V, et al. Novel STAT1 gain-of-function mutation and suppurative infections. *Pediatr Allergy Immunol* (2016) 27:220–3. doi:10.1111/pai.12496

118. Dotta L, Scomodon O, Padoan R, Timpano S, Plebani A, Soresina A, et al. Clinical and immunological data of nine patients with chronic mucocutaneous candidiasis disease. *Data Brief* (2016) 7:311–5. doi:10.1016/j.dib.2016.02.040

119. Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. *J Allergy Clin Immunol* (2013) 131:1624–34. doi:10.1016/j.jaci.2013.01.052

120. Frans G, Moens L, Schaballie H, Van Eyck L, Borgers H, Wuyts M, et al. Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding. *J Allergy Clin Immunol* (2014) 134:1209–13. doi:10.1016/j.jaci.2014.05.044

121. Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, et al. Dominant gain-of-function STAT1 mutations in FOXP3(WT) IPEX-like syndrome. *J Allergy Clin Immunol* (2013) 131:1611.e–23.e. doi:10.1016/j.jaci.2012.11.054

122. Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. *Nat Genet* (2014) 46:812–4. doi:10.1038/ng.3040

123. Haapaniemi EM, Kaustio M, Rajala HLM, van Adrichem AJ, Kainulainen I, Glumoff V, et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. *Blood* (2015) 125:639–48. doi:10.1182/blood-2014-04-570101

124. Giardino G, Aloj G, Cirillo E, Capalbo D, Maio F, Salerno M, et al. Intergenerational anticipation of disease onset in people with multiple autoimmune syndrome. *Diabetes Res Clin Pract* (2011) 94:e37–9. doi:10.1016/j.diabres.2011.07.022

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2016 Giardino, Gallo, Prencipe, Gaudino, Romano, De Cataldis, Lorello, Palamaro, Di Giacomo, Capalbo, Cirillo, D’Assante and Pignata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*